| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.07 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.27 | 0.08 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.081 | 0.08 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.28 | 0.08 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.25 | 0.08 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.11 | 0.08 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.19 | 0.08 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.08 |